Sotatercept for Connective Tissue Disease-Associated Pulmonary Arterial Hypertension with Concomitant Interstitial Lung Disease: Efficacy and Safety Insights

COMMENTED

Interstitial Lung Disease

ERS/EULAR clinical practice guidelines for connective tissue disease-associated interstitial lung diseaseDeveloped by the task force for connective tissue disease-associated interstitial lung disease of the European Respiratory Society (ERS) and the European Alliance of Associations for Rheumatology (EULAR)Endorsed by the European Reference Network on rare respiratory diseases (ERN-LUNG)

★ 3 Recommended and commented by Dr Marcus Hesse, Faculty Member

Eur Respir J

Antoniou KM, Distler O, Gheorghiu AM, Moor CC, Vikse J, Bizymi N, Galetti I, Brown G, Bargagli E, Allanore Y, Corte TJ, Dieudé P, Cottin V, Fisher BA, Fabre A, Giles JT, Kreuter M, Lundberg IE, Poletti V, Maurer B, Renzoni EA, Müller-Ladner U, Strek ME, Sverzellati N, Studenic P, Mohammed J, Nagavci B, Stamm T, Tonia T, Crestani B, Hoffmann-Vold AM

doi: 10.1183/13993003.02533-2024

Interstitial Lung DiseasePneumonia

High-Resolution CT Findings in Interstitial Lung Disease Associated with Connective Tissue Diseases: Differentiating Patterns for Clinical Practice-A Systematic Review with Meta-Analysis

J Clin Med

Drimus JC, Duma RC, Trăilă D, Mogoșan CD, Manolescu DL, Fira-Mladinescu O

doi: 10.3390/jcm14176164

Further Publications

Efficacy and Safety of Sotatercept Across Ranges of Cardiac Index in Patients with Pulmonary Arterial Hypertension: A Pooled Analysis of PULSAR and STELLAR

J Heart Lung Transplant

Gomberg-Maitland M, Badesch DB, Gibbs JSR, Grünig E, Hoeper MM, Humbert M, Kopeć G, McLaughlin VV, Meyer G, Olsson KM, Preston IR, Rosenkranz S, Souza R, Waxman AB, Perchenet L, Strait J, Xing A, Johnson-Levonas AO, Cornell AG, Pena JO, Ardeschir Ghofrani H

doi: 10.1016/j.healun.2024.11.037

RECOMMENDED

Pulmonary Hypertension

Consistent Safety and Efficacy of Sotatercept for Pulmonary Arterial Hypertension in BMPR2 Mutation Carriers and Noncarriers: A Planned Analysis of Phase 2, Double-Blind, Placebo-controlled Clinical Trial (PULSAR)

★ 2 Recommended by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Am J Respir Crit Care Med

Montani D, McLaughlin VV, Gibbs JSR, Gomberg-Maitland M, Hoeper MM, Preston IR, Souza R, Waxman AB, Escribano Subias P, Feldman J, Meyer GM, Olsson KM, Coulet F, Manimaran S, Zhao Y, Lau A, de Oliveira Pena J, Badesch DB, Humbert M

doi: 10.1164/rccm.202409-1698OC

RECOMMENDED

COPDInterstitial Lung Disease

Pulmonary Rehabilitation and Functional Independence: Impact on Survival in Patients with Fibrotic Interstitial Lung Disease or Chronic Obstructive Pulmonary Disease

★ 2 Recommended by Dr Martin Frey, Faculty Member

★ 3 Recommended by Dr Marcus Hesse, Faculty Member

Respir Med

Elmiger A, Marcin T, Bovet L, Brun P, Guler SA

doi: 10.1016/j.rmed.2024.107933

RECOMMENDED

Interstitial Lung DiseasePulmonary Fibrosis

Association Between Calcium Channel Blocker Use and the Risk of Interstitial Lung Disease and Idiopathic Pulmonary Fibrosis: A Longitudinal Cohort Study

★ 2 Recommended by Dr Martin Frey, Faculty Member

★ 2 Recommended by Dr Marcus Hesse, Faculty Member

Respir Med

Jang HJ, Seong YM, Jeong J, Huh JY, Kim JH, Kim KH, Park JH, Choi WI

doi: 10.1016/j.rmed.2025.107939

Pulmonary Hypertension

Global, regional, and national burden of pulmonary arterial hypertension, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021

Lancet Respir Med

GBD 2021 Pulmonary Arterial Hypertension Collaborators

doi: 10.1016/S2213-2600(24)00295-9

RECOMMENDED

Interstitial Lung DiseasePneumonia

Clinical Profiles, Survival, and Lung Function Outcomes in ANCA-Associated Interstitial Lung Disease: An Observational Study

★ 3 Recommended by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

J Clin Med

Valero-Martínez C, Valenzuela C, Baldivieso Achá JP, Martínez-Besteiro E, Quiroga-Colina P, Alfranca A, Vicente-Rabaneda EF, Muñiz SH, Castañeda S, García-Vicuña R

doi: 10.3390/jcm14010229

COMMENTED

Interstitial Lung DiseaseFurther Publications

Performance of Lung Ultrasound as a Screening Tool for Subclinical Rheumatoid Arthritis-Associated Interstitial Lung Disease: a Multicenter Study

★ 3 Recommended and commented by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Chest

Maria O, Eirini V, Sébastien O, Marwin G, Soledad DM, Adrian G, Pierre-Antoine J, Chiara B, Nestor A, Christos S, Maricel DM, Paola O, Alan QR, Marie-Pierre D, Barbara PC, Emilce S, Prodromos S, Nicolas LS, Marcos R, Sebastian M, Katerina A

doi: 10.1016/j.chest.2024.11.038

Related content

High-Resolution CT Findings in Interstitial Lung Disease Associated with Connective Tissue Diseases: Differentiating Patterns for Clinical Practice-A Systematic Review with Meta-Analysis

Efficacy and Safety of Sotatercept Across Ranges of Cardiac Index in Patients with Pulmonary Arterial Hypertension: A Pooled Analysis of PULSAR and STELLAR

Consistent Safety and Efficacy of Sotatercept for Pulmonary Arterial Hypertension in BMPR2 Mutation Carriers and Noncarriers: A Planned Analysis of Phase 2, Double-Blind, Placebo-controlled Clinical Trial (PULSAR)

Pulmonary Rehabilitation and Functional Independence: Impact on Survival in Patients with Fibrotic Interstitial Lung Disease or Chronic Obstructive Pulmonary Disease

Association Between Calcium Channel Blocker Use and the Risk of Interstitial Lung Disease and Idiopathic Pulmonary Fibrosis: A Longitudinal Cohort Study

Global, regional, and national burden of pulmonary arterial hypertension, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021

Clinical Profiles, Survival, and Lung Function Outcomes in ANCA-Associated Interstitial Lung Disease: An Observational Study

Performance of Lung Ultrasound as a Screening Tool for Subclinical Rheumatoid Arthritis-Associated Interstitial Lung Disease: a Multicenter Study